CY1118255T1 - Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3 - Google Patents
Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3Info
- Publication number
- CY1118255T1 CY1118255T1 CY20161101222T CY161101222T CY1118255T1 CY 1118255 T1 CY1118255 T1 CY 1118255T1 CY 20161101222 T CY20161101222 T CY 20161101222T CY 161101222 T CY161101222 T CY 161101222T CY 1118255 T1 CY1118255 T1 CY 1118255T1
- Authority
- CY
- Cyprus
- Prior art keywords
- nicotinamides
- amino
- substituted
- kcnq2
- modulators
- Prior art date
Links
- ZLWYEPMDOUQDBW-UHFFFAOYSA-N 6-aminonicotinamide Chemical class NC(=O)C1=CC=C(N)N=C1 ZLWYEPMDOUQDBW-UHFFFAOYSA-N 0.000 title abstract 2
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 title 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12002709 | 2012-04-18 | ||
| PCT/EP2013/001134 WO2013156154A1 (en) | 2012-04-18 | 2013-04-17 | Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators |
| EP13719386.8A EP2888233B1 (en) | 2012-04-18 | 2013-04-17 | Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118255T1 true CY1118255T1 (el) | 2017-06-28 |
Family
ID=48227140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101222T CY1118255T1 (el) | 2012-04-18 | 2016-11-24 | Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2888233B1 (enExample) |
| JP (1) | JP6033403B2 (enExample) |
| CN (1) | CN104428287A (enExample) |
| AR (1) | AR090739A1 (enExample) |
| AU (1) | AU2013248637A1 (enExample) |
| BR (1) | BR112014025840A2 (enExample) |
| CA (1) | CA2870573A1 (enExample) |
| CY (1) | CY1118255T1 (enExample) |
| DK (1) | DK2888233T3 (enExample) |
| EA (1) | EA201401142A1 (enExample) |
| ES (1) | ES2605947T3 (enExample) |
| HK (1) | HK1210173A1 (enExample) |
| HR (1) | HRP20161424T1 (enExample) |
| HU (1) | HUE030859T2 (enExample) |
| IL (1) | IL235030A0 (enExample) |
| LT (1) | LT2888233T (enExample) |
| MX (1) | MX2014012494A (enExample) |
| PT (1) | PT2888233T (enExample) |
| RS (1) | RS55466B1 (enExample) |
| SI (1) | SI2888233T1 (enExample) |
| WO (1) | WO2013156154A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3447047A1 (en) * | 2016-04-22 | 2019-02-27 | ONO Pharmaceutical Co., Ltd. | Crystal polymorphism of kcnq 2-5 channel activator |
| WO2019130185A1 (en) * | 2017-12-29 | 2019-07-04 | 3M Innovative Properties Company | Thermally curable two part processing adhesive composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2230392A1 (de) | 1972-06-22 | 1974-01-31 | Cassella Farbwerke Mainkur Ag | Substituierte pyridinverbindungen und verfahren zu ihrer herstellung |
| DE2513949A1 (de) | 1975-03-29 | 1976-10-07 | Bayer Ag | Azofarbstoffe |
| CZ20032233A3 (cs) | 2001-02-20 | 2004-12-15 | Bristol-Myers Squibb Company | Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ |
| MXPA03007397A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas. |
| EP2086935A1 (de) * | 2006-10-16 | 2009-08-12 | Grünenthal GmbH | Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren |
| DE102006049452A1 (de) | 2006-10-17 | 2008-05-08 | Grünenthal GmbH | Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln |
| JP2012506395A (ja) | 2008-10-24 | 2012-03-15 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 痛み、てんかん、及び尿失禁の治療のためのｋｃｎｑ２／３モジュレーターとしての置換された４，５，６，７−テトラヒドロチエノピリジン |
| TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
| CA2815131C (en) * | 2010-10-20 | 2020-06-09 | Gruenenthal Gmbh | Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
-
2013
- 2013-04-17 DK DK13719386.8T patent/DK2888233T3/en active
- 2013-04-17 BR BR112014025840A patent/BR112014025840A2/pt not_active IP Right Cessation
- 2013-04-17 HK HK15111080.1A patent/HK1210173A1/xx unknown
- 2013-04-17 HR HRP20161424TT patent/HRP20161424T1/hr unknown
- 2013-04-17 ES ES13719386.8T patent/ES2605947T3/es active Active
- 2013-04-17 LT LTEP13719386.8T patent/LT2888233T/lt unknown
- 2013-04-17 AU AU2013248637A patent/AU2013248637A1/en not_active Abandoned
- 2013-04-17 PT PT137193868T patent/PT2888233T/pt unknown
- 2013-04-17 EP EP13719386.8A patent/EP2888233B1/en not_active Not-in-force
- 2013-04-17 HU HUE13719386A patent/HUE030859T2/en unknown
- 2013-04-17 JP JP2015506121A patent/JP6033403B2/ja not_active Expired - Fee Related
- 2013-04-17 CN CN201380019282.3A patent/CN104428287A/zh active Pending
- 2013-04-17 EA EA201401142A patent/EA201401142A1/ru unknown
- 2013-04-17 SI SI201330394A patent/SI2888233T1/sl unknown
- 2013-04-17 RS RS20161120A patent/RS55466B1/sr unknown
- 2013-04-17 WO PCT/EP2013/001134 patent/WO2013156154A1/en not_active Ceased
- 2013-04-17 CA CA2870573A patent/CA2870573A1/en not_active Abandoned
- 2013-04-17 MX MX2014012494A patent/MX2014012494A/es unknown
- 2013-04-18 AR ARP130101283A patent/AR090739A1/es unknown
-
2014
- 2014-10-07 IL IL235030A patent/IL235030A0/en unknown
-
2016
- 2016-11-24 CY CY20161101222T patent/CY1118255T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013156154A1 (en) | 2013-10-24 |
| EP2888233B1 (en) | 2016-09-28 |
| AR090739A1 (es) | 2014-12-03 |
| CN104428287A (zh) | 2015-03-18 |
| AU2013248637A1 (en) | 2014-12-04 |
| BR112014025840A2 (pt) | 2017-07-18 |
| CA2870573A1 (en) | 2013-10-24 |
| JP2015514728A (ja) | 2015-05-21 |
| JP6033403B2 (ja) | 2016-11-30 |
| EA201401142A1 (ru) | 2015-03-31 |
| HRP20161424T1 (hr) | 2016-12-16 |
| HK1210173A1 (en) | 2016-04-15 |
| DK2888233T3 (en) | 2017-01-09 |
| SI2888233T1 (sl) | 2016-12-30 |
| HUE030859T2 (en) | 2017-06-28 |
| EP2888233A1 (en) | 2015-07-01 |
| PT2888233T (pt) | 2017-01-04 |
| MX2014012494A (es) | 2015-01-15 |
| ES2605947T3 (es) | 2017-03-17 |
| RS55466B1 (sr) | 2017-04-28 |
| LT2888233T (lt) | 2017-01-10 |
| IL235030A0 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| EA201491505A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| CY1118379T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
| EA033374B1 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201391106A1 (ru) | Новые гетероциклические производные | |
| CY1120204T1 (el) | Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο | |
| EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| UA116999C2 (uk) | Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου |